Skip to main content
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 Feb;150(2):727–734.

Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

N Iliskovic 1, P K Singal 1
PMCID: PMC1858278  PMID: 9033285

Abstract

The contribution of lipid lowering in protection against adriamycin cardiomyopathy achieved by probucol, an antioxidant and a lipid-lowering drug, was assessed by comparing its beneficial effects with that of lovastatin, another lipid-lowering drug with no known antioxidant properties. Adriamycin (cumulative dose, 15 mg/kg body weight) was given to rats in 6 equal injections (intraperitoneally) over a period of 2 weeks. Probucol (cumulative dose, 120 mg/kg body weight) or lovastatin (cumulative dose, 48 mg/kg body weight) was given in 12 equal injections (intraperitoneally) before and concurrent with adriamycin. After 3 weeks of post-treatment with adriamycin, congestive heart failure, ascites, congested liver, and depressed cardiac function were seen. Adriamycin treatment decreased glutathione peroxidase activity and increased lipid peroxidation. Adriamycin increased plasma triglycerides, total cholesterol, and high- and low-density lipoproteins. Myocardial triglycerides and total cholesterol were also increased. Probucol completely prevented the development of congestive heart failure and normalized myocardial and plasma triglycerides and total cholesterol, and significantly decreased plasma high- and low-density lipoproteins. Lovastatin significantly attenuated but did not completely prevent cardiomyopathic changes due to adriamycin. Lovastatin decreased plasma total cholesterol and low-density lipoproteins as well as myocardial triglycerides and total cholesterol. Plasma triglycerides and high-density lipoproteins were still high in the adriamycin plus lovastatin group. Probucol improved glutathione peroxidase activity and reduced lipid peroxidation whereas lovastatin had no effect on these adriamycin-induced changes. These data suggest that adriamycin cardiomyopathy is associated with an antioxidant deficit as well as increased myocardial and plasma lipids. Complete protection by probucol against adriamycin-induced congestive heart failure may be due to the unique combination of its antioxidant and lipid-lowering properties.

Full text

PDF
727

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adriamycin-induced myocardial lesions. Report of a workshop. Am J Surg Pathol. 1977 Mar;1(1):55–60. doi: 10.1097/00000478-197701010-00006. [DOI] [PubMed] [Google Scholar]
  2. Bremer J. Carnitine--metabolism and functions. Physiol Rev. 1983 Oct;63(4):1420–1480. doi: 10.1152/physrev.1983.63.4.1420. [DOI] [PubMed] [Google Scholar]
  3. Bristow M. R., Sageman W. S., Scott R. H., Billingham M. E., Bowden R. E., Kernoff R. S., Snidow G. H., Daniels J. R. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol. 1980 Sep-Oct;2(5):487–515. doi: 10.1097/00005344-198009000-00002. [DOI] [PubMed] [Google Scholar]
  4. Bristow M. R., Thompson P. D., Martin R. P., Mason J. W., Billingham M. E., Harrison D. C. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov;65(5):823–832. doi: 10.1016/0002-9343(78)90802-1. [DOI] [PubMed] [Google Scholar]
  5. Buja L. M., Ferrans V. J., Mayer R. J., Roberts W. C., Henderson E. S. Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973 Oct;32(4):771–788. doi: 10.1002/1097-0142(197310)32:4<771::aid-cncr2820320407>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  6. Chalcroft S. C., Gavin J. B., Herdson P. B. Fine structural changes in rat myocardium induced by daunorubicin. Pathology. 1973 Apr;5(2):99–105. doi: 10.3109/00313027309060824. [DOI] [PubMed] [Google Scholar]
  7. Doroshow J. H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983 Feb;43(2):460–472. [PubMed] [Google Scholar]
  8. Doroshow J. H., Locker G. Y., Myers C. E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980 Jan;65(1):128–135. doi: 10.1172/JCI109642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gosálvez M., van Rossum G. D., Blanco M. F. Inhibition of sodium-potassium-activated adenosine 5'-triphosphatase and ion transport by adriamycin. Cancer Res. 1979 Jan;39(1):257–261. [PubMed] [Google Scholar]
  10. Joles J. A., van Tol A., Jansen E. H., Koomans H. A., Rabelink T. J., Grond J., van Goor H. Plasma lipoproteins and renal apolipoproteins in rats with chronic adriamycin nephrosis. Nephrol Dial Transplant. 1993;8(9):831–838. [PubMed] [Google Scholar]
  11. Kalyanaraman B., Perez-Reyes E., Mason R. P. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta. 1980 Jun 5;630(1):119–130. doi: 10.1016/0304-4165(80)90142-7. [DOI] [PubMed] [Google Scholar]
  12. Kaul N., Siveski-Iliskovic N., Hill M., Slezak J., Singal P. K. Free radicals and the heart. J Pharmacol Toxicol Methods. 1993 Oct;30(2):55–67. doi: 10.1016/1056-8719(93)90008-3. [DOI] [PubMed] [Google Scholar]
  13. Kunitomo M., Yamaguchi Y., Matsushima K., Futagawa Y., Bandô Y. Hyperlipidemic effects of adriamycin in rats. Jpn J Pharmacol. 1985 Nov;39(3):323–329. doi: 10.1254/jjp.39.323. [DOI] [PubMed] [Google Scholar]
  14. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  15. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  16. Mettler F. P., Young D. M., Ward J. M. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977 Aug;37(8 Pt 1):2705–2713. [PubMed] [Google Scholar]
  17. Modi K. S., Morrissey J., Shah S. V., Schreiner G. F., Klahr S. Effects of probucol on renal function in rats with bilateral ureteral obstruction. Kidney Int. 1990 Nov;38(5):843–850. doi: 10.1038/ki.1990.280. [DOI] [PubMed] [Google Scholar]
  18. Myers C. E., McGuire W. P., Liss R. H., Ifrim I., Grotzinger K., Young R. C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977 Jul 8;197(4299):165–167. doi: 10.1126/science.877547. [DOI] [PubMed] [Google Scholar]
  19. Olson H. M., Capen C. C. Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest. 1977 Oct;37(4):386–394. [PubMed] [Google Scholar]
  20. Olson H. M., Young D. M., Prieur D. J., LeRoy A. F., Reagan R. L. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 1974 Dec;77(3):439–454. [PMC free article] [PubMed] [Google Scholar]
  21. Paglia D. E., Valentine W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967 Jul;70(1):158–169. [PubMed] [Google Scholar]
  22. Placer Z. A., Cushman L. L., Johnson B. C. Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem. 1966 Aug;16(2):359–364. doi: 10.1016/0003-2697(66)90167-9. [DOI] [PubMed] [Google Scholar]
  23. Singal P. K. Adriamycin does have a potentially depressant effect on left ventricular contractility. Int J Cardiol. 1985 Apr;7(4):447–449. doi: 10.1016/0167-5273(85)90103-2. [DOI] [PubMed] [Google Scholar]
  24. Singal P. K., Deally C. M., Weinberg L. E. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 Aug;19(8):817–828. doi: 10.1016/s0022-2828(87)80392-9. [DOI] [PubMed] [Google Scholar]
  25. Singal P. K., Forbes M. S., Sperelakis N. Occurrence of intramitochondrial Ca2+ granules in a hypertrophied heart exposed to adriamycin. Can J Physiol Pharmacol. 1984 Sep;62(9):1239–1244. doi: 10.1139/y84-207. [DOI] [PubMed] [Google Scholar]
  26. Singal P. K., Panagia V. Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol. 1984 Jan;43(1):67–77. [PubMed] [Google Scholar]
  27. Siveski-Iliskovic N., Hill M., Chow D. A., Singal P. K. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995 Jan 1;91(1):10–15. doi: 10.1161/01.cir.91.1.10. [DOI] [PubMed] [Google Scholar]
  28. Siveski-Iliskovic N., Kaul N., Singal P. K. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994 Jun;89(6):2829–2835. doi: 10.1161/01.cir.89.6.2829. [DOI] [PubMed] [Google Scholar]
  29. Skutelsky E., Hartzan S., Socher R., Gafter U. Modifications in glomerular polyanion distribution in adriamycin nephrosis. J Am Soc Nephrol. 1995 Apr;5(10):1799–1805. doi: 10.1681/ASN.V5101799. [DOI] [PubMed] [Google Scholar]
  30. Steinherz L. J., Steinherz P. G., Tan C. T., Heller G., Murphy M. L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 Sep 25;266(12):1672–1677. [PubMed] [Google Scholar]
  31. Tong J., Ganguly P. K., Singal P. K. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991 Mar;260(3 Pt 2):H909–H916. doi: 10.1152/ajpheart.1991.260.3.H909. [DOI] [PubMed] [Google Scholar]
  32. Washio M., Nanishi F., Okuda S., Onoyama K., Fujishima M. Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure. Nephron. 1994;68(3):347–352. doi: 10.1159/000188398. [DOI] [PubMed] [Google Scholar]
  33. Weinberg L. E., Singal P. K. Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Can J Physiol Pharmacol. 1987 Sep;65(9):1957–1965. doi: 10.1139/y87-305. [DOI] [PubMed] [Google Scholar]
  34. Willerbrands A. F., ter Welle H. F., Tasseron S. J. The effect of a high molar FFA-albumin ratio in the perfusion medium on rhythm and contractility of the isolated rat heart. J Mol Cell Cardiol. 1973 Jun;5(3):259–273. doi: 10.1016/0022-2828(73)90066-7. [DOI] [PubMed] [Google Scholar]
  35. Yeung S. T., Yoong C., Spink J., Galbraith A., Smith P. J. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991 Apr 6;337(8745):816–818. doi: 10.1016/0140-6736(91)92516-5. [DOI] [PubMed] [Google Scholar]
  36. Zbinden G., Bachmann E., Holderegger C. Model systems for cardiotoxic effects of anthracyclines. Antibiot Chemother (1971) 1978;23:255–270. doi: 10.1159/000401489. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES